Cenicriviroc for the treatment of fibrosis
AssigneeTobira Therapeutics, Inc.
InventorEric Lefebvre
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvent thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), or emerging cirrhosis.
Claims24
A method of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising cenicriviroc or a salt or solvate thereof and fumaric acid,
- wherein the pharmaceutical composition further comprises fumaric acid at a weight ratio of cenicriviroc or a salt or solvate thereof to fumaric acid selected from the group consisting of:
- a) from about 7:10 to about 10:7;
- b) from about 8:10 to about 10:8;
- and c) from about 95:100 to about 100:95.
(canceled)
(canceled)
A method of treating NASH in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition cenicriviroc, or a salt or solvate thereof and fumaric acid;
- wherein the NASH is associated with type 2 diabetes mellitus (T2DM), metabolic syndrome (MS), or HIV and HCV co-infection.
-12. (canceled)
20-23. (canceled)
A method of treatment efficacy of fibrosis or a fibrotic disease or condition in a subject suffering from said disease or condition, the method comprising:
- (a) obtaining a first biological sample from said subject;
- (b) measuring a level or levels of one or more biological molecules in the first biological sample;
- and,
- (c) comparing the level or levels obtained from the first biological sample to a level or levels of biological molecules from a predetermined standard in a healthy subject;
- wherein the relative increase in level or levels of the biological molecules is indicative of treatment efficacy;
- wherein the biological molecule is selected from the group consisting of lipopolysaccharide (LPS), LPs-binding protein (LBP), 16S rDNA, sCD14, intestinal fatty acid binding protein (I-FABP), zonulin-1, Collagen 1a1 and 3a1, TGF-β, fibronectin-1, hs-CRP, IL-1β, IL-6, IL-33, fibrinogen, MCP-1, MIP-1α and −1β, RANTES, sCD163, TGF-β, TNF-α, a biomarker of hepatocyte apoptosis, and a combination thereof.
Dependencies are inferred from the claim text.